We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

292 hedge funds and large institutions have $5.8B invested in Xenon Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 123 increasing their positions, 60 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more capital inflows, than outflows

Capital inflows: $1.1B | Capital outflows: $332M

148% more first-time investments, than exits

New positions opened: 82 | Existing positions closed: 33

105% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 60

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

18% more funds holding

Funds holding: 247 → 292 (+45)

8% less call options, than puts

Call options by funds: $127M | Put options by funds: $138M

5.58% less ownership

Funds ownership: 109.26% → 103.68% (-5.6%)

Holders
292
Holders Change
+45
Holders Change %
+18.22%
% of All Funds
3.54%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.15%
New
82
Increased
123
Reduced
60
Closed
33
Calls
$127​M
Puts
$138​M
Net Calls
-⁠$11​M
Net Calls Change
+$7.38​M

XENE Hedge Fund Activity: Q1 2026 in Review

292 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2026, worth a combined $5.8B — up 53% from $3.78B a quarter earlier.

Buyers outnumbered sellers: 82 funds opened new XENE positions and 33 closed out — a net gain of 49 holders — while 123 added to existing stakes and 60 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $89.4M. The largest seller was Commodore Capital, cutting an estimated $44.9M.

  • 292 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2026, up from 247 in Q4 2025.
  • Funds reported $5.8B of Xenon Pharmaceuticals stock for Q1 2026, up 53% quarter-over-quarter.
  • 82 funds opened new Xenon Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +49 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2026 was Polar Capital Holdings, an estimated $89.4M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2026 was Commodore Capital, an estimated $44.9M sold.

Based on aggregated 13F filings for Q1 2026.